[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 15 sources · 2 days · First seen · Last updated

Advancements in prostate cancer treatments

Overview

Recent developments in prostate cancer therapy have focused on new drug approvals and clinical trial results aimed at reducing metastasis and recurrence risks.

In the United States, the FDA approved the combination of talazoparib and enzalutamide for treating metastatic hormone-sensitive prostate cancer in patients with homologous recombination repair (HRR) gene mutations. This follows the phase 3 TALAPRO-3 trial, which indicated that adding talazoparib to enzalutamide reduced the risk of radiographic progression or death by 52%.

At the 2026 European Society for Medical Oncology congress, further clinical data were presented. The Phase 3 Dasl-Hicap study found that combining darolutamide, androgen deprivation therapy, and locoregional radiotherapy reduced the risk of metastasis or death by 58% in high-risk patients. Additionally, the Phase 3 PROTEUS sub-study showed that administering apalutamide with androgen deprivation therapy perioperatively reduced the risk of disease recurrence or death by 62% compared to radical prostatectomy alone.

Entities

Johnson & Johnson · Bayer · Astellas · talazoparib · Pfizer

Timeline

  1. [HEALTH] 11 sources
    Prostate cancer treatments show significant reduction in metastasis risk

    Clinical trials presented at ESMO 2026 show that darolutamide and apalutamide, combined with hormone therapy, significantly reduce the risk of metastasis and death in high-risk prostate cancer patients.

  2. [HEALTH] 4 sources
    FDA approves talazoparib and enzalutamide for metastatic prostate cancer

    The FDA approved talazoparib and enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer, reducing the risk of progression or death by 52% in clinical trials.

Sources

calabrianews.it · cancernetwork.com · e-sante.fr · farmaciavirtuale.it · immedicohospitalario.es · innlifes.com · karitas.si · lecodellitorale.it · lsdmagazine.com · notizie.it · pcf.org · quotidianodelsud.it · redazionenews.it · timelines.issarice.com · trapanisi.it